Literature DB >> 16131313

Evidence for host-driven selection of the HIV type 1 vpr gene in vivo during HIV disease progression in a transfusion-acquired cohort.

Leon Cali1, Bin Wang, Meriet Mikhail, Michael J Gill, Brenda Beckthold, Marco Salemi, David A Jans, Sabine C Piller, Nitin K Saksena.   

Abstract

An epidemiologically linked HIV-1-infected cohort, in which a nonprogressor donor infected two recipients who progressed to AIDS, was examined. Sequence analysis, over time, of HIV-1 vpr gene quasispecies from uncultured peripheral blood cells revealed an insertion of arginine at position 90 altering a highly conserved C-terminal motif, believed to play a role in Vpr nuclear targeting. Full genome analysis from each patient showed no gene defects in other gene regions, implying that the mutational selection was unique to the vpr gene. A detailed analysis of the vpr quasispecies showed very little amino acid diversity in the nonprogressing donor, whereas, following viral transmission, the amino acid diversity increased dramatically over time in tandem with disease progression in the two recipients. Although the R insertion at position 90 was present in all three individuals, the variable degree of additional amino acid changes over time may have influenced HIV disease in the nonprogressor donor and the two progressing recipients. These data provide the first evidence in favor of vpr gene evolution over time, which was host-driven. The status of the nonprogressing donor was consistent with a highly protective B-57 HLA type, which was absent in the two progressing recipients, implying a role for host HLA type and other immunologic selective pressures in vpr gene selection in vivo.

Entities:  

Mesh:

Year:  2005        PMID: 16131313     DOI: 10.1089/aid.2005.21.728

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  7 in total

1.  SIV Vpr evolution is inversely related to disease progression in a morphine-dependent rhesus macaque model of AIDS.

Authors:  Richard J Noel; Anil Kumar
Journal:  Virology       Date:  2006-10-24       Impact factor: 3.616

Review 2.  Defining the roles for Vpr in HIV-1-associated neuropathogenesis.

Authors:  Tony James; Michael R Nonnemacher; Brian Wigdahl; Fred C Krebs
Journal:  J Neurovirol       Date:  2016-04-07       Impact factor: 2.643

3.  Identification and molecular characterization of SIV Vpr R50G mutation associated with long term survival in SIV-infected morphine dependent and control macaques.

Authors:  Ivelisse Rivera; Yashira García; Mohitkumar R Gangwani; Richard J Noel; Lucianette Maldonado; Anil Kumar; Vanessa Rivera-Amill
Journal:  Virology       Date:  2013-08-28       Impact factor: 3.616

4.  Mass culling of minks to protect the COVID-19 vaccines: is it rational?

Authors:  R Frutos; C A Devaux
Journal:  New Microbes New Infect       Date:  2020-11-17

5.  Role of spike compensatory mutations in the interspecies transmission of SARS-CoV-2.

Authors:  Roger Frutos; Nouara Yahi; Laurent Gavotte; Jacques Fantini; Christian A Devaux
Journal:  One Health       Date:  2022-08-29

6.  The immunosuppressive properties of the HIV Vpr protein are linked to a single highly conserved residue, R90.

Authors:  Irina Tcherepanova; Aijing Starr; Brad Lackford; Melissa D Adams; Jean-Pierre Routy; Mohamed Rachid Boulassel; David Calderhead; Don Healey; Charles Nicolette
Journal:  PLoS One       Date:  2009-06-10       Impact factor: 3.240

7.  Impaired nuclear import and viral incorporation of Vpr derived from a HIV long-term non-progressor.

Authors:  Leon Caly; Nitin K Saksena; Sabine C Piller; David A Jans
Journal:  Retrovirology       Date:  2008-07-18       Impact factor: 4.602

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.